Reported about 7 hours ago
Pfizer and Bristol Myers Squibb are both facing challenges related to patent expirations, yet they are attractively priced and offer strong dividend yields of 7% and 5.7% respectively. Pfizer is focusing on its oncology pipeline and new products, while Bristol Myers has secured approvals for innovations in its cancer treatments. Despite current setbacks, both companies show promise for long-term recovery and growth, making them appealing options for value and income-oriented investors.
Source: YAHOO